



Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Claim 1 (currently amended) A method for preventing or treating neurodegenerative disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula (II):



Formula (I)



Formula (II)

wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,


R₁, R₂, R₃, R₄, R₅ and R₆ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl [()wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano()].

Claim 2 (original) The method of claim 1 wherein X is chlorine.

Claim 3 (original) The method of claim 1 wherein X is substituted at the ortho position of the phenyl ring.

Claim 4 (original) The method of claim 1 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are selected from hydrogen.

Claim 5 (currently amended) A method for preventing or treating neurodegenerative disorders comprising administering to a subject in need thereof a therapeutically effective amount of an enantiomer selected from the group consisting of Formula (I) and Formula (II) or enantiomeric mixture wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates:



wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

R₁, R₂, R₃, R₄, R₅ and R₆ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl [()wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano[]].

Claim 6 (original) The method of claim 5 wherein X is chlorine.


Claim 7 (original) The method of claim 5 wherein X is substituted at the ortho position of the phenyl ring.

Claim 8 (original) The method of claim 5 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are selected from hydrogen.

Claim 9 (original) The method of claim 5 wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 90% or greater.

Claim 10 (original) The method of claim 5 wherein one enantiomer selected from the group consisting of Formula (I) and Formula (II) predominates to the extent of about 98% or greater.

Claim 11 (currently amended) The method of claim 5 wherein the enantiomer selected from the group consisting of Formula (I) and Formula (II) is an enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa):



wherein

phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and,

R₁, R₂, R₃, R₄, R₅ and R₆ are independently selected from the group consisting of hydrogen and C₁-C₄ alkyl; wherein C₁-C₄ alkyl is optionally substituted with phenyl [()wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, amino, nitro and cyano()].

Claim 12 (original) The method of claim 11 wherein X is chlorine.


Claim 13 (original) The method of claim 11 wherein X is substituted at the ortho position of the phenyl ring.

Claim 14 (original) The method of claim 11 wherein R₁, R₂, R₃, R₄, R₅ and R₆ are selected from hydrogen.


Claim 15 (original) The method of claim 11 wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 90% or greater.

Claim 16 (original) The method of claim 11 wherein one enantiomer selected from the group consisting of Formula (Ia) and Formula (IIa) predominates to the extent of about 98% or greater.

Claim 17 (original) The method of claim 5 wherein the enantiomer selected from the group consisting of Formula (I) and Formula (II) is an enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb):



Formula (Ib)



Formula (IIb)

Claim 18 (original) The method of claim 17 wherein one enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 90% or greater.

Claim 19 (original) The method of claim 17 wherein one enantiomer selected from the group consisting of Formula (Ib) and Formula (IIb) predominates to the extent of about 98% or greater.

Claim 20 (currently amended) The method as in claim 1 wherein neurodegenerative disorders are selected from the group consisting of acute neurodegenerative disorders, chronic neurodegenerative disorders, other acute and [or] chronic neurodegenerative disorders associated with memory loss and other acute and [or] chronic neurodegenerative disorders associated with neuronal injury.

Claim 21 (currently amended) The method of claim 20 wherein acute neurodegenerative disorders are selected from neurodegenerative disorders associated with an abrupt insult selected from acute injury, hypoxia-ischemia and [or] the combination thereof resulting in neuronal cell death or compromise.

Claim 22 (currently amended) The method of claim 21 wherein acute injury is selected from brain trauma, focal brain trauma, diffuse brain damage, spinal cord injury, intracranial lesions [()selected from contusion, penetration, shear, compression or laceration lesions()], intravertebral lesions [()selected from contusion, penetration, shear, compression and [or] laceration lesions()] and [or] whiplash shaken infant syndrome.

Claim 23 (currently amended) The method of claim 22 wherein acute injury is selected from brain trauma, focal brain trauma, diffuse brain damage and [or] spinal cord injury.

Claim 24 (currently amended) The method of claim 21 wherein hypoxia-ischemia is selected from cerebrovascular insufficiency, cerebral ischemia and [or] cerebral infarction.

Claim 25 (currently amended) The method of claim 24 wherein cerebral ischemia or cerebral infarction are selected from cerebral ischemias and [or] infarctions originating from embolic occlusion, thrombotic occlusion, reperfusion following acute ischemia, perinatal hypoxic-ischemic injury, cardiac arrest and [or] intracranial hemorrhage [() wherein hemorrhage is selected from epidural, subdural, subarachnoid and [or] intracerebral hemorrhage ()].

Claim 26 (currently amended) The method of claim 20 wherein chronic neurodegenerative disorders are selected from neurodegenerative disorders associated with progressive neuronal cell death or compromise over a period of time selected from Alzheimer's disease, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy [()selected from Steele-Richardson syndrome()], multisystem degeneration [()selected from Shy-Drager syndrome()], chronic epileptic conditions associated with neurodegeneration, motor neuron diseases [()selected from amyotrophic lateral sclerosis()], multiple sclerosis, degenerative ataxias, cortical basal degeneration, ALS-Parkinson's-Dementia complex of Guam, subacute sclerosing panencephalitis, Huntington's disease, Parkinson's disease, synucleinopathies [()selected from multiple system atrophy()], primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease / spinocerebellar ataxia type 3 and olivopontocerebellar degenerations, bulbar and pseudobulbar palsy, spinal and spinobulbar muscular atrophy [()selected from Kennedy's disease()], primary lateral sclerosis, familial spastic paraparesia, Werdnig-Hoffmann disease, Kugelberg-Welander disease, Tay-Sach's disease, Sandhoff disease, familial spastic disease, Wohlfart-Kugelberg-Welander disease, spastic paraparesis, progressive multifocal leukoencephalopathy, familial dysautonomia [()selected from Riley-Day syndrome()] and [or] prion diseases [()selected from Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, Kuru disease and [or] fatal familial insomnia()].

Claim 27 (currently amended) The method of claim 26 wherein chronic neurodegenerative disorders are selected from Alzheimer's disease, chronic epileptic conditions associated with neurodegeneration, multiple sclerosis and [or] Parkinson's disease.

Claim 28 (currently amended) The method of claim 20 wherein other acute or chronic neurodegenerative disorders associated with memory loss are selected from neurodegenerative disorders associated with age-related dementia, vascular dementia, diffuse white matter disease [()selected from Binswanger's disease()], dementia of endocrine and [or] metabolic origin, dementia of head trauma and [or] diffuse brain damage, dementia pugilistica and [or] frontal lobe dementia.

Claim 29 (currently amended) The method of claim 20 wherein other acute or chronic neurodegenerative disorders associated with neuronal injury are selected from neurodegenerative disorders associated with chemical, toxic, infectious and radiation injury of the nervous system, injury during fetal development, prematurity at time of birth, anoxic-ischemia, injury from hepatic, glycemic, uremic, electrolyte and endocrine origin, injury of psychiatric origin, injury from peripheral diseases and plexopathy [()selected from plexus palsies()] and [or] injury from neuropathy.

Claim 30 (currently amended) The method of claim 29 wherein other acute or chronic neurodegenerative disorders associated with neuronal injury are selected from neurodegenerative disorders associated with injury of psychiatric origin and [or] injury from neuropathy.

Claim 31 (currently amended) The method of claim 30 wherein injury of psychiatric origin is selected from psychopathology, depression and [or] anxiety; and, wherein injury from neuropathy is selected from multifocal, sensory, motor, sensory-motor, autonomic, sensory-autonomic and [or] demyelinating neuropathies [()selected from Guillain-Barre syndrome and [or] chronic inflammatory demyelinating polyradiculoneuropathy()] and [or] those neuropathies originating from infections, inflammation, immune disorders, drug abuse, pharmacological treatments, toxins, trauma [()selected from compression, crush, laceration and [or] segmentation traumas], metabolic disorders (selected from endocrine and [or]

Serial No. 10/797,795

paraneoplastic[]], Charcot-Marie-Tooth disease [()selected from type 1a, 1b, 2, 4a and [or] 1-X linked[]], Friedreich's ataxia, metachromatic leukodystrophy, Refsum's disease, adrenomyeloneuropathy, Ataxia-telangiectasia, Déjerine-Sottas [()selected from types A and [or] B[]], Lambert-Eaton syndrome and [or] disorders of the cranial nerves[]].

Claim 32 (previously amended) The method as in claims 1 wherein the therapeutically effective amount is from about 0.01 mg/Kg/dose to about 100 mg/Kg/dose.